Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Isospec Analytics raises $1.9m as it introduces breakthrough technology to rapidly identify unknown molecules at scale

Isospec Analytics

When developing new drugs, nutitional products, or pesticides, it’s critical that unknown molecules are identified correctly. But accurate identification is a lengthy process and all too often unsuccessful, leading to failed regulatory processes, or worse, consumer health being put in danger. Today, Isospec Analytics has raised $1.9M to commercialize new technologies for molecular analysis that rapidly identify unknown molecules in minutes, helping pharmaceuticals, nutrition and agritech companies develop safer products and enabling researchers to discover new biomarkers. Isospec’s $1.9M pre-seed round is led by Founderful (formerly Wingman Ventures), with additional participation from specialized investors Tiny.vc, another.vc and Venture Kick. Isospec was founded in 2022 by Ahmed Ben Faleh, Stephan Warnke, and Thomas Rizzo, who partnered together to explore how they could redefine the process of molecular analysis to access new biological information and enable breakthroughs in diagnostics, therapeutics, and nutrition. Based on over 20 years of research, the founders combined technologies from multiple disciplines – analytical chemistry, photonics, and cryogenic materials initially designed for space applications – to build a tool that can generate a new data dimension about molecular structures. This allows for the identification of molecules which were, until now, unknown. Today, identifying an unknown molecule is primarily based on mass analysis, which does not provide sufficient information. Identifying a by-product or an impurity requires the combination of high sensitivity to detect trace amounts in a sample, coupled with the ability to generate data that can definitively identify the structure of a molecule. Existing tools lack either one or both of these capabilities. “Unfortunately, mass alone does not uniquely determine the structure of a molecule. Several different molecules can have exactly the same mass, called isomers, but totally different properties. For example, one isomer might be toxic, while another may be a life-saving therapeutic,” said Thomas Rizzo, Professor of Chemistry at EPFL. Definitive molecular identification currently requires the combination of several techniques and a lengthy process including purification and multiple syntheses. Companies developing new products are thus faced with a dilemma: either spend months identifying unknowns and delay their go-to-market, or move forward based on guesses and risk failing regulatory requirements and endanger consumer health. In comparison, Isospec’s technology generates unique, information-rich metrics that allow for the rapid identification of unknown molecules in minutes instead of months, bringing unprecedented scalability to molecular identification. “By adding infrared analysis directly inside a mass spectrometer, we have a valuable new dimension by which to identify molecules,” adds Professor Thomas Rizzo. Originating from the Laboratory of Molecular Physical Chemistry (LCPM) at EPFL, Isospec’s breakthrough technology is already being used in the analysis of sugars and metabolites within the food and agritech industry to carry out quality control and support product R&D. However, the team believes the real potential of their technology is in the discovery of new biomarkers for therapeutics development and diagnostics. “In a human blood sample, there are 15,000 small biological molecules that can give precise information about a person’s health at any given time. However, less than 5% of these molecules can be identified. The ability to rapidly identify new molecules means we can now leverage the 95% unknown molecular space to develop treatments to the deadliest diseases,” said co-founder and CEO Dr. Ahmed Ben Faleh. These combined use cases were compelling for Isospec’s investors. “Isospec’s value proposition, which offers early access to its cutting-edge research in biomolecular analysis as a service, convinced us of the potential of the technology and the team,” explains Alex Stöckl, partner at Founderful and board member of Isospec. “Isospec is one of the first 8 companies in which we have invested with our second fund, which aims to reach $120M.” The team is currently working on the scalability of their platform, introducing automation at every step and implementing machine learning tools for data analysis and insight generation. “This round allows us to build a software team composed of experts in data engineering,” said Dr Ahmed Ben Faleh. Against the highly competitive backdrop of the sugar and metabolite analytical markets, Isospec is setting its sights on becoming the leading provider of molecular analysis solutions and biomarker discovery technology. About Isospec Isospec Analytics is an EPFL spin-off based in Lausanne – Switzerland, whose mission is to implement technology to discover new disease biomarkers, accelerate the development of therapeutics and transform the future of clinical nutrition. For more information please visit IsoSpec Analytics About Founderful Founderful is Switzerland’s leading pre-seed fund. We give every founder our deepest understanding and highest levels of support, and together, we’re building the future of the Swiss startup ecosystem. Contact Details isospec Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.isospecanalytics.com/

April 16, 2024 08:00 AM Eastern Daylight Time

Image

News Release

NuggMD to Again Offer Cannabis Support Line, the Too-High Hotline, on 4/20

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine platform, is once again helping accidental cannabis over-indulgers find support this 4/20 with its Too-High Hotline. The hotline (323-518-2728), first established last April, is a resource for consumers who, for whatever reason—cough, cough—want a friendly voice who will converse with them, calm them down, or just listen. States have seen an explosion in much-needed harm- and anxiety-reduction measures, thanks to the reduced stigma around cannabis use. Still, many Americans resist seeking help for highly emotional psychedelic experiences because cannabis is still illegal at the federal level. This results in unguided use by consumers who are unprepared to handle unusual mental effects. It is why emergency-room visits for the overconsumption of cannabis usually spike on April 20. “To be clear: Yes, this is a real service. Anyone who consumes, or consumes too much, this April 20 can call us and talk to us about whatever they want to. No judgments,” said Alex Milligan, co-founder and CMO of NuggMD. He continued: “There is also a serious side to the 4/20 holiday that I hope gets more attention this year. The cannabis movement acknowledges the need for harm-reduction measures as the substance continues to gain mainstream acceptance. Use of the plant affects different people in different ways, and the truth is that some of those effects are negative or unpleasant. So, beyond setting up the Too-High Hotline every April, we are committed to consumer empowerment and education every day throughout the year.” NuggMD’s Too-High Hotline is available to everyone in the United States this 4/20 to offer support during or after their cannabis experience. NuggMD is also educating patients about harm reduction and support options through a dedicated landing page, nationwide email notifications to its network of more than a million patients, and additional ongoing campaigns focused on harm reduction and safe consumption. To learn more about NuggMD’s Too High Hotline, please visit https://www.nuggmd.com/support. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 1,300,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit https://www.nuggmd.com. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

April 15, 2024 04:41 PM Eastern Daylight Time

CoverSelf appoints Ashish Singh, Advisory Partner at Bain & Company, as Board Director

CoverSelf

CoverSelf, a unified platform for healthcare claims and payment integrity, is today announcing the appointment of Ashish Singh, Advisory Partner at Bain & Company, as Board Director. This development comes on the heels of the company’s recent close of a $8.2 million seed round. Ashish is a well-known and deeply respected Bain & Company leader. He led Bain’s global Healthcare and Life Sciences (HLS) practice from 2012 to 2018 and served two terms on Bain’s global Board of Directors in the same time period. Ashish also founded Bain & Company’s India office and was at its helm as Managing Director (2005-2011) and Chairman (2011-2014). Over the years, he also co-founded Bain’s Enterprise Software, Media & Entertainment, Pharmaceutical and Payer practices. Ashish’s expertise lies in corporate and BU strategies, market entry strategies, operational improvement, organisational effectiveness, M&A, healthcare IT, and large-scale corporate transformation programs. “We are thrilled to welcome Ashish onboard as our Board Director. He is a veteran in this space and brings invaluable experience in formulating overall strategy and US GTM strategy, as well as in-depth knowledge of the US healthcare system and health plans. Not to mention, his broad network of relationships across the industry will benefit us in the long term,” said Rajasekhar Maddireddy, Co-founder of CoverSelf. “We’ve been busy since our funding announcement. We are already live as the secondary editor in three health plans, with an expansion to another four over the next six months in the works. We are in full-scale implementation with a top 10 health plan, and executing a PoC with a Top 5 health plan. These are showing remarkable results, wherein the platform is processing 25 times more claims in the same time window than was done earlier. We will soon start initial moves into markets adjacent to the payment integrity (PI) space via collaboration with a focused set of partners to bring broader integrated solutions to our clients.” CoverSelf was founded in 2021 by US healthcare domain experts Rajasekhar Maddireddy and Raghavendra Pawar to tackle the ever-increasing claims inaccuracies and waste. The company aims to democratize the healthcare claims and payment integrity industry by creating a first-of-its-kind, fully open and transparent solution that empowers payment integrity teams in health insurance companies (payers) to transparently resolve health claims with hospitals and medical practices (providers). CoverSelf’s purpose-built platform utilizes multiple approaches, including the smart use of GenAI, to reduce waste while identifying new savings opportunities. The platform empowers payers to adapt to claims and payment inaccuracies by enabling them to configure their policies and logic in simple English-like language or use simple policy-specific templates, overcoming the fear of losing IP and fostering innovation and new concept releases without technical dependencies. “According to recent reports, the $9 billion PI industry has grown at around 7% CAGR in recent years. This just shows the inherent complexity of the billing processes. The truth is, over the years, there has been a perceptible negative impact on providers' experience with payments, and trust in payers has taken a significant hit. This has resulted in ballooning waste and improper payments. Given this scenario, I’m glad to lend a helping hand to CoverSelf’s mission,” said Ashish Singh, Board Director of CoverSelf. “I will work closely with the co-founders and top management to increase Coverself's visibility amongst healthcare payers and technology partners and also bring my expertise to assist them in corporate and market strategy. What we are doing in CoverSelf is not just building a product that is looking to solve a few pain points; we are on a once-in-a-lifetime mission to truly democratize healthcare claims and payment integrity and restore faith in the US’s healthcare ecosystem!” About CoverSelf CoverSelf is a generational leap forward in healthcare claims and Payment Integrity architecture, built from the ground up for healthcare-specific use by passionate domain experts and strong technology professionals with decades of experience in addressing the pain points faced by Providers and Payers when dealing with the latest technological advancements. Founded in 2021, CoverSelf’s Payment Integrity Platform engages modern technologies to address payment leakage & claims inaccuracies while remaining transparent & accessible to Payers. The platform empowers payers to prevent and adapt to the ever-evolving claims & payment inaccuracies. We also help you reduce complexity and administrative costs with our unified healthcare dedicated platform. Contact Details CoverSelf Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.coverself.com/

April 15, 2024 09:59 AM Pacific Daylight Time

Image

Comtex Launches Omnia: A Cutting-Edge News API Platform leveraging NLP and AI

Comtex

Comtex News Network, Inc (Comtex), a leading provider of news aggregation and distribution services to top firms in financial services, news publishing, syndication, and analytics, proudly announces the launch of its innovative API platform, Omnia. Omnia is a state-of-the-art API platform designed to revolutionize the way businesses access and utilize news content. Omnia empowers users with instant access to real-time streaming news, AI-generated article summaries, enhanced tagging and categorization based on NLP, advanced filtering, and access to an extensive catalog of curated news sources. Key Features of Omnia Include: Real-time Streaming News: Omnia provides real-time streaming news via websockets push and REST API for seamless integration into existing systems. Enhanced Tagging and Categorization: Leveraging AI and proprietary NLP-based algorithms, Omnia offers enhanced tagging and categorization of content, including press releases, earnings releases, product categories, and more. AI-Generated Article Summaries: Omnia utilizes AI to generate concise and searchable article summaries, enabling users to quickly grasp an article before reading it. Advanced Filtering: Omnia's advanced filtering capabilities allow users to customize their news feeds based on specific criteria, ensuring they receive only the most relevant content. Access to an extensive collection of curated, high-quality sources used by top companies in financial services, analytics, research and a broad range of industries. Omnia is designed for rapid integration and serves a variety of use cases, including training of LLMs, financial platforms, asset management, trading, academic research, legal research, market research, and much more. Commenting on the launch, Comtex CEO Kan Devnani said, "We are pleased to bring a flexible, state-of-the-art news platform with access to curated, premium news sources to market. Omnia is an extendable platform, combining AI with our rich experience applying NLP to news content. This will allow clients to derive more intelligence and insights from the news content we offer and help clients curate and identify the content most relevant to them. Comtex will use Omnia to deliver evolving analytics and insight to its users." Access to Omnia can be trialed by visiting https://www.comtex.com/api. Comtex encourages users to explore its features and capabilities. To learn more about Omnia and request a demo, please contact sales@comtex.com or visit https://www.comtex.com/api. About Comtex News Network, Inc (Comtex): Comtex News Network Inc (Comtex) is a leading provider of news aggregation services to top firms in financial services, news publishing, syndication, and analytics. With a wealth of experience and expertise, Comtex delivers comprehensive news solutions that empower businesses to make informed decisions and stay ahead of the competition. Comtex also offers syndication services to content providers and platforms to generate traffic to online content. Contact Details Comtex News Network Media Relations sales@comtex.com

April 12, 2024 02:01 PM Eastern Daylight Time

Game-Changing Tumor Freezing Technology Has The Potential To Offer Women First-Ever Minimally Invasive Alternative To Breast Lumpectomy Surgery

Benzinga

By Meg Flippin, Benzinga IceCure Medical Ltd. (NASDAQ: ICCM), which is set to submit results from the largest cryoablation study of its kind to the FDA, may set a new standard of care for early-stage breast cancer in women who elect not to have surgery. This could be a game-changer for the medical community and IceCure alike. When it comes to the early onset of breast cancer, the typical treatment protocol is for women to undergo a lumpectomy followed by chemotherapy, hormone or radiation therapy. The lumpectomy involves removing the tumor and some healthy tissue around it surgically in a hospital operating room. It requires heavy sedation, is often painful and has a long recovery time. While tens of thousands of lumpectomies are performed annually in the U.S., it is not a perfect solution. In about 20% of cases, a second surgical procedure known as a re-excision is required to get rid of lingering cancer cells. Some tumors are difficult to spot or feel which makes them hard to locate during the surgery and thus follow-up surgeries are often required. Re-excision can not only be costly, it adds to the recovery time and weighs on the patient’s mental health. Some women, concerned about their future, opt at that point for a mastectomy. Freezing Tumors May Be The Answer With about 280,000 women diagnosed with invasive breast cancer each year, and around 340,000 total cases, finding better alternatives is front and center for many healthcare providers, drug companies and biotechs including IceCure Medical Ltd. (NASDAQ: ICCM). IceCure is expanding the use of ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Cryoablation is a potentially attractive option for treating tumors because it is minimally invasive and has little pain associated with it. Tumors can be seen clearly by using imaging modalities like ultrasound or computerized tomography (CT), accurately destroying diseased tissue within the tumor zone. Cryoablation reduces surgery-related complications, downtime for the patient and economic burden to the insurer and the medical provider, as well as reducing the need for secondary lumpectomy in breast cancer. IceCure likens its ProSense procedure for breast tumors to that of going to the dentist, with no scarring or general anesthesia required. Rather, IceCure relies on lidocaine used locally so there is no need to go to a hospital or stay overnight to recover, all of which reduces costs and speeds up recovery. Unlike lumpectomies, cryoablation does not involve the excision of breast tissue, thereby eliminating many of the adverse cosmetic effects of tumor excision as well. Some researchers have even called cryoablation the “ultimate esthetic solution for breast cancer” because it reduces the need for pre-emptive or corrective surgical procedures to maintain or restore breast volume, contour and symmetry. For all of those reasons, breast cancer cryoablation has emerged as a possible alternative to lumpectomy for early-stage breast cancer over the past decade. Promising Topline Results IceCure recently announced positive topline results from its ICE3 study, which it says is the largest controlled multicenter clinical trial ever performed in the U.S. for liquid nitrogen (LN2) based cryoablation of low-risk, early-stage malignant breast tumors, following the five-year follow-up evaluation of the ICE3 study's last patient. In the ICE3 study, 96.39% of patients (187 out of 194 patients) were local recurrence-free with no significant device-related adverse events or complications reported. Based on those topline results, the company said ProSense has the potential to be a safe and effective alternative to lumpectomy for early-stage breast cancer. The company says it is on track to submit the full data set and results to the U.S. Food and Drug Administration (FDA) for marketing clearance any day now, and Prosense is already approved for breast cancer in other territories like Europe. The breast cancer market size is significant, and was valued at $31.89 billion in 2022 and is forecast to hit $70.53 billion by 2030, growing at a CAGR of 10.43% over 2023-2030. The tumor ablation market is expected to reach $2.4 billion by 2028, growing at a CAGR of 13.2% from now until then. "We are very pleased with this topline outcome and believe these results demonstrate a highly favorable safety and efficacy profile that positions ProSense® as a desirable alternative to lumpectomy for early-stage breast cancer," said Eyal Shamir, Chief Executive Officer of IceCure. "While the FDA evaluates the data, we are optimistic its upcoming decision will give women in the U.S. the same access as those who are already benefiting from ProSense® in other countries,” he said. ProSense has regulatory approval in 15 countries for a broad range of indications including in Europe, Brazil, Canada and China. Incidents of breast cancer are increasing around the world, with many people facing invasive and time-consuming procedures. While lumpectomies will continue to be necessary sometimes, companies like IceCure may be giving patients an alternative way to fight this disease. With full data being submitted to the FDA any day now, if approved it could prove to be game-changing for IceCure and women across America diagnosed with early-stage breast cancer. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 12, 2024 01:35 PM Eastern Daylight Time

Image

Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovascular Tests

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more precise, has inked a new deal with an innovative digital health technology platform. Cardio Diagnostics’ strategic partnership with Navierre — which revolutionizes how patients access healthcare by acting as a true health companion for every stage of life — aims to significantly expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests. On April 1, Cardio Diagnostics’ precision heart health solutions, including its flagship AI-powered epigenetic-genetic cardiovascular risk, detection and management tests, became available to thousands of patients and clinicians on Navierre’s platform. Now, Navierre-partnered clinicians across the United States can seamlessly order these tests for their patients. Consumers can easily register for a profile on the platform by filling out a health questionnaire and requesting a test. Those clinical tests, Epi+Gen CHD and PrecisionCHD, only require a blood sample that can be collected in provider settings, at home or via mobile phlebotomy. This ease of collection will enable Cardio Diagnostics’ partnership with Navierre to leverage the growing telehealth market and revolutionize the patient cardiovascular care journey through earlier detection, accessible specialty care and personalized prevention. “We are thrilled to partner with Navierre to make our industry-leading cardiovascular clinical tests more widely available to patients and clinicians nationwide,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “Navierre’s innovative platform aligns with our mission to transform cardiovascular care through AI-driven precision diagnostics and personalized prevention strategies.” Cardiovascular Market Growth Nearly 50% of Americans live with diabetes, obesity, hypertension or another major cardiovascular risk, according to the Centers for Disease Control and Prevention (CDC). Cardiovascular disease is the leading cause of death worldwide, accounting for nearly 19 million deaths annually. This impact on a growing number of people across the world means the demand for cardiovascular diagnostics has never been higher. Companies in the field are in a position to achieve robust growth as they strive to meet the demand. Projections indicate a Compound Annual Growth Rate (CAGR) of 5.1% in the cardiovascular diagnostics market, whose market valuation is expected to reach $9.7 billion by 2033. This surge can be attributed to the escalating demand for sophisticated and accessible diagnostic technologies in the fight against cardiovascular diseases. Following this upward trend, the digital health and telehealth markets are poised for growth that has been fueled by the rapid adoption of telehealth services and the integration of AI technologies. The AI healthcare market, which is also poised for significant growth, had an estimated size of $22.45 billion in 2023, a number that’s expected to accelerate at a CAGR of 36.4%. Finally, the telehealth market, with a valuation of $128.12 billion in 2022, is forecasted to quadruple by 2030 to $504.24 billion. These developments have changed the healthcare landscape and underscore the Cardio Diagnostics-Navierre partnership’s positioning to capitalize on these market shifts. Navierre provides a digital health platform that can integrate Cardio Diagnostics’ tests into a broader telehealth ecosystem, expanding access and facilitating earlier cardiovascular risk detection. That means the flexibility of Cardio Diagnostics’ tests will pave the way for rapid nationwide scaling with minimal infrastructure barriers. Thus, the partnership could make specialty cardiology care more readily available for all communities, including those that are often underserved. By expanding the sites of care to telehealth and remote-enabled provider organizations, this partnership addresses the critical issue of increasing wait times for specialty care while democratizing access to top-tier heart disease services. This collaboration directly responds to current diagnostic methods' limitations, offering a scalable solution that extends to remote zip codes in the U.S. Advances In The Fight Against The Top Cause Of Death The COVID-19 pandemic has accelerated the adoption of digital health solutions, with the CDC reporting that 36% of adults used telehealth services in 2021. McKinsey & Company estimates that up to $250 billion of U.S. healthcare spending could be virtualized, representing about 20% of all Medicare, Medicaid and commercial outpatient, office and home health expenditures. This shift to digital health and AI-driven diagnostics could have a broad impact on the cardiovascular detection, care and management industry. Across the country, there is a need for more accessible and systemic healthcare solutions. This new partnership offers an important response to the goal of combating cardiovascular diseases globally while committing to health equity and access. “Cardio Diagnostics’ groundbreaking testing solutions are an exciting addition to our curated list of products and services we offer to our users,” said Mustafa Dinani, CEO and co-founder of Navierre. “By combining our innovative platform with their AI-driven precision diagnostics, we empower patients and clinicians with the tools they need to identify cardiovascular risk early when it can be most effectively addressed. Together, we are making significant strides in the fight against the world’s leading cause of death,” he said. Featured photo by Ali Hajiluyi on Unsplash Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

April 12, 2024 08:45 AM Eastern Daylight Time

Image

Select Sector SPDR ETFs: A Strategic Approach to Precision Investing and Customized Portfolios

Select Sector SPDR

In the dynamic world of investing, Exchange-Traded Funds ( ETFs ) have proved to be a powerful tool for investors seeking diversification, flexibility, and potentially a more sector-driven approach. Select Sector SPDR ETFs offer a focused approach to sector investing, enabling investors to specifically target sectors within the broader market. This method of investment strategy is designed to arm investors with greater control and flexibility over their portfolios. Select Sector SPDR ETFs segment the S&P 500 into 11 investable sectors, covering all broad market segments. They provide access to various industries, allowing investors to craft a diversified portfolio that aligns with their unique investment goals. This approach presents an excellent opportunity for both individual and institutional investors to effectively navigate the financial markets. Each ETF comprises well-known, large-cap companies from the S&P 500, ensuring broad exposure and diversification. The transparent nature of ETFs allows for daily disclosure of portfolio holdings and weightings, providing investors with visibility into their investments. The full lineup of Select Sector SPDR ETFs includes: Communication Services Select Sector SPDR Fund (XLC) Consumer Discretionary Select Sector SPDR Fund (XLY) Consumer Staples Select Sector SPDR Fund (XLP) Energy Select Sector SPDR Fund (XLE) Financials Select Sector SPDR Fund (XLF) Health Care Select Sector SPDR Fund (XLV) Industrials Select Sector SPDR Fund (XLI) Materials Select Sector SPDR Fund (XLB) Real Estate Select Sector SPDR Fund (XLRE) Technology Select Sector SPDR Fund (XLK) Utilities Select Sector SPDR Fund (XLU) These ETFs provide flexible, transparent, and low-cost investment options to both retail and institutional investors. The flexibility offered by these ETFs empowers investors to make strategic adjustments in their portfolios as market conditions change. This flexibility, combined with the transparency of daily disclosure of portfolio holdings, allows investors to always be aware of where their money is invested. Select Sector SPDR ETFs offer a unique opportunity to invest in various sectors with precision and flexibility. They provide a simplified approach to sector investing, allowing investors to customize their portfolios to meet their specific investment objectives. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007439 EXP 5/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

April 12, 2024 05:00 AM Eastern Daylight Time

News Release

Most cannabis consumers would vote for pro-cannabis candidates regardless of party, new polling finds

NuggMD

A majority of cannabis consumers who are likely to vote this November would cast their ballot for a pro-cannabis presidential candidate regardless of that candidate’s party, according to a new poll that sheds light on how aligned cannabis consumers are as a voting bloc and what they think about this year's presidential election. When asked whether a presidential candidate’s endorsement of pro-cannabis policies would increase their likelihood of voting for that candidate, 59% of the respondents said: “Yes, this would make me more likely to vote for that candidate regardless of their party.” Just 14% of respondents said they are locked into voting for their party or candidate of choice. The poll was conducted by NuggMD.com, the largest telehealth platform for cannabis, using its own first-party data. The full results are available on the company’s website. It shows President Biden outperforming Donald Trump, 43% to 36%, among those who use cannabis regularly, a population of at least 35 million voting-age people. President Biden also polled well ahead of a generic Republican candidate, while Trump was roughly tied with a generic Democratic candidate. Concerning cannabis policy, the Democratic Party polled better than the GOP among this audience. Fifty-six percent of respondents said Democratic electeds have better ideas for cannabis policy, compared to 16% who said the same of Republicans. But this support is neither universal nor particularly intense. Nearly 40% of respondents indicated that they believe Democrats “want to suppress the legal use of cannabis,” while 68% said the same of Republicans. While 88% of respondents said understanding cannabis culture is a requirement for writing and passing effective cannabis legislation, 73% said elected officials in general currently lack that understanding. “This poll shows that adopting pro-cannabis policies can move more constituents into either party’s camp,” said Deb Tharp, head of legal and policy research at NuggMD. “This is a large voting population we’re talking about, and its demographics are changing quickly.” She continued: “Respondents say they’re motivated by policy commitments and wins, not by grievance politics, outrage, or red meat. The degree to which this emerging constituency is moveable, and how to move them, will probably come as a surprise to insiders of both parties. “To me, it signals that Republicans are shooting themselves in the foot by continuing to embrace the platform of prohibition. Democrats should double down on cannabis and expand their voting base by embracing full decriminalization and expungement for victims of targeted, unjust enforcement.” Methodology NuggMD.com conducted the poll digitally from March 25 to April 3 using a random sample of its first-party data. In total, 53,380 individuals were contacted and 755 completed the survey, resulting in a margin of error of 3.89% at a confidence level of 95%. Six swing states (n=120 in aggregate) were over-indexed. The full data set is available upon request. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 1,300,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit https://www.nuggmd.com. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

April 11, 2024 12:28 PM Eastern Daylight Time

Autonomix Medical (NASDAQ: AMIX) Is Cracking the Code Of The Peripheral Nervous System With Its Breakthrough Technology To Treat Diseases

Autonomix Medical, Inc.

By Faith Ashmore, Benzinga The peripheral nervous system (PNS) is the network of nerves that extend from the brain and spinal cord to all parts of the body. Its main function is to facilitate communication between the central nervous system (CNS) and the rest of the body. The PNS is divided into two components: the somatic nervous system, which controls voluntary movements and senses, and the autonomic nervous system, which controls involuntary bodily functions like heart rate and digestion. Simply put, the PNS plays a crucial role in nearly every disease because it is responsible for transmitting signals and information throughout the body. Overactive nerves, disruption, or dysfunction in the PNS can lead to a variety of health issues, including conditions like pain, cardiovascular disease, such as hypertension, as well as gastrointestinal disorders. While many biotechnology companies are looking to treat symptoms for various conditions, Autonomix Medical Inc. (NASDAQ: AMIX) is targeting the root of the issue, which they associate with the PNS. The company’s first-in-class technology platform includes a catheter-based microchip sensing array that can detect and differentiate neural signals and perform nerve ablations, killing the nerve. This technology has the ability to sense individual neural signals with up to 3,000 times greater sensitivity than currently available technologies. The company says this breakthrough technology opens new possibilities in electrophysiology and pain management. Autonomix Medical aims to provide a comprehensive solution that combines the detection and treatment of nerve-related disorders in a single procedure, streamlining the process and potentially improving patient outcomes. Unlike the conventional ablation approaches, Autonomix Medical reports that its technology works like a GPS, allowing doctors to identify, treat and verify the right nerves causing the issue. The company is initially evaluating pancreatic cancer pain to demonstrate the ability of its technology. With current treatment options, pancreatic cancer-related pain can be particularly challenging to manage because it is located near critical nerves and vessels, leading to severe and treatment resistant pain. Traditional pain treatments can often prove inadequate, leaving patients in need of more effective solutions; some patients turn to opioids for relief. If Autonomix Medical’s ongoing trial is successful, it could pave the way for the company to target larger disease markets and expand the total opportunity for their technology, which they estimate exceeds $100 billion. Additionally, Autonomix believes it has the potential to decrease nationwide reliance on opioids, which could be a win for patients and physicians alike. Featured photo by Stefano Bucciarelli on Unsplash Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC autonomix@jtcir.com Company Website https://autonomix.com/

April 11, 2024 08:55 AM Eastern Daylight Time

Image

1 ... 39 40 41 42 43 ... 305